GBI has launched its first information content product, the China Pharmaceutical and Biotechnology Review (CPB Review). The CPB Review provides in-depth analysis and timely coverage of China’s pharmaceutical and biotechnology sectors, highlighting burgeoning trends and developments through exclusive, original articles and interviews with industry leaders.
The CPB Review distinguishes itself from other China healthcare periodicals by leveraging unique information from GBI databases to bolster expert commentary from China healthcare professionals. CPB Review subscribers are privy to a wide range of insider analytics – including a selection of the most important monthly news briefs, line by line analysis of crucial government policies and their impact, and cutting-edge perspectives written by in-the-know professionals – providing critical analysis and forward-looking insights into a complex and increasingly important market.